Published in J Alzheimers Dis on January 01, 2010
Curcumin and Apigenin - novel and promising therapeutics against chronic neuroinflammation in Alzheimer's disease. Neural Regen Res (2015) 1.47
Protective Effects of Dietary Supplementation with a Combination of Nutrients in a Transgenic Mouse Model of Alzheimer's Disease. PLoS One (2015) 1.39
Docosahexaenoic acid reduces amyloid beta production via multiple pleiotropic mechanisms. J Biol Chem (2011) 1.10
Nutrition and prevention of Alzheimer's dementia. Front Aging Neurosci (2014) 0.92
Clustering of midlife lifestyle behaviors and subsequent cognitive function: a longitudinal study. Am J Public Health (2014) 0.84
The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease. Alzheimers Res Ther (2013) 0.83
Use of medical foods and nutritional approaches in the treatment of Alzheimer's disease. Clin Pract (Lond) (2012) 0.81
A Dietary Treatment Improves Cerebral Blood Flow and Brain Connectivity in Aging apoE4 Mice. Neural Plast (2016) 0.81
Current Research Therapeutic Strategies for Alzheimer's Disease Treatment. Neural Plast (2016) 0.80
Dysfunction of the neurovascular unit in ischemic stroke and neurodegenerative diseases: An aging effect. Ageing Res Rev (2016) 0.77
Broad-based nutritional supplementation in 3xTg mice corrects mitochondrial function and indicates sex-specificity in response to Alzheimer's disease intervention. J Alzheimers Dis (2012) 0.77
Primary prevention of Alzheimer's disease: is it an attainable goal? J Korean Med Sci (2014) 0.77
Omega-3 Fatty Acid Status Enhances the Prevention of Cognitive Decline by B Vitamins in Mild Cognitive Impairment. J Alzheimers Dis (2016) 0.75
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Mild cognitive impairment. Lancet (2006) 10.21
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol (2006) 6.97
The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol (2010) 4.59
Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum Brain Mapp (2005) 4.11
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 3.65
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol (2007) 3.22
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement (2011) 3.05
Small vessel disease and general cognitive function in nondisabled elderly: the LADIS study. Stroke (2005) 2.59
Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. Stroke (2008) 2.57
Cognitive impairment in heart failure: a systematic review of the literature. Eur J Heart Fail (2006) 2.56
Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry (2010) 2.44
Profile of cognitive impairment in chronic heart failure. J Am Geriatr Soc (2007) 2.43
Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia Aging Study. Hypertension (2004) 2.43
Brain imaging in patients with diabetes: a systematic review. Diabetes Care (2006) 2.39
Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem (2009) 2.32
Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging (2010) 2.27
Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain (2003) 2.20
Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ɛ4 allele. Lancet Neurol (2010) 2.18
Loss of 'small-world' networks in Alzheimer's disease: graph analysis of FMRI resting-state functional connectivity. PLoS One (2010) 2.12
Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology (2004) 2.00
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement (2013) 1.98
Advances in the early detection of Alzheimer's disease. Nat Med (2004) 1.97
Impact of age-related cerebral white matter changes on the transition to disability -- the LADIS study: rationale, design and methodology. Neuroepidemiology (2005) 1.92
Impact of white matter hyperintensities scoring method on correlations with clinical data: the LADIS study. Stroke (2006) 1.88
Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiol Aging (2008) 1.82
Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI study. Neuroradiology (2007) 1.80
Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol (2006) 1.79
Shining a light on posterior cortical atrophy. Alzheimers Dement (2012) 1.77
Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med (2009) 1.77
Imaging markers for Alzheimer disease: which vs how. Neurology (2013) 1.76
Deficits of memory, executive functioning and attention following infarction in the thalamus; a study of 22 cases with localised lesions. Neuropsychologia (2003) 1.76
On the etiology of incident brain lacunes: longitudinal observations from the LADIS study. Stroke (2008) 1.75
Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem (2004) 1.68
Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol Aging (2008) 1.67
Microbleeds do not affect rate of cognitive decline in Alzheimer disease. Neurology (2012) 1.62
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement (2011) 1.59
Model-free group analysis shows altered BOLD FMRI networks in dementia. Hum Brain Mapp (2009) 1.59
Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol (2007) 1.57
Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition. Stroke (2009) 1.57
Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. J Alzheimers Dis (2012) 1.57
White matter tract integrity in aging and Alzheimer's disease. Hum Brain Mapp (2009) 1.57
Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients. Radiology (2008) 1.56
Early-versus late-onset Alzheimer's disease: more than age alone. J Alzheimers Dis (2010) 1.54
Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging (2011) 1.54
Diffusion changes predict cognitive and functional outcome: the LADIS study. Ann Neurol (2013) 1.54
Functional neural network analysis in frontotemporal dementia and Alzheimer's disease using EEG and graph theory. BMC Neurosci (2009) 1.54
Altered temporal correlations in parietal alpha and prefrontal theta oscillations in early-stage Alzheimer disease. Proc Natl Acad Sci U S A (2009) 1.54
CSF biomarker levels in early and late onset Alzheimer's disease. Neurobiol Aging (2008) 1.52
Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology (2013) 1.51
Diagnostic accuracy of consensus diagnostic criteria for frontotemporal dementia in a memory clinic population. Dement Geriatr Cogn Disord (2008) 1.51
Activity dependent degeneration explains hub vulnerability in Alzheimer's disease. PLoS Comput Biol (2012) 1.50
EEG abnormalities in early and late onset Alzheimer's disease: understanding heterogeneity. J Neurol Neurosurg Psychiatry (2010) 1.48
Heterogeneity in age-related white matter changes. Acta Neuropathol (2011) 1.47
The clinical profile of right temporal lobe atrophy. Brain (2009) 1.46
Noradrenaline mediates amygdala activation in men and women during encoding of emotional material. Neuroimage (2005) 1.45
Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol (2003) 1.43
Brain magnetic resonance imaging abnormalities in patients with heart failure. Eur J Heart Fail (2007) 1.42
Cognitive impairment and MRI correlates in the elderly patients with type 2 diabetes mellitus. Age Ageing (2007) 1.40
2001-2011: A Decade of the LADIS (Leukoaraiosis And DISability) Study: What Have We Learned about White Matter Changes and Small-Vessel Disease? Cerebrovasc Dis (2011) 1.40
CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. Neurobiol Aging (2007) 1.39
Low vitamin B6 levels are associated with white matter lesions in Alzheimer's disease. J Am Geriatr Soc (2005) 1.38
Cerebral blood flow measured with 3D pseudocontinuous arterial spin-labeling MR imaging in Alzheimer disease and mild cognitive impairment: a marker for disease severity. Radiology (2012) 1.38
Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain (2011) 1.33
Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimers Dement (2012) 1.31
Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients. Ann Neurol (2003) 1.28
Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology (2013) 1.27
Vascular factors and markers of inflammation in offspring with a parental history of late-onset Alzheimer disease. Arch Gen Psychiatry (2009) 1.27
Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol (2010) 1.26
Longitudinal cognitive decline in subcortical ischemic vascular disease--the LADIS Study. Cerebrovasc Dis (2009) 1.25
Neuroimaging and correlates of cognitive function among patients with heart failure. Dement Geriatr Cogn Disord (2007) 1.25
Alzheimer's disease: connecting findings from graph theoretical studies of brain networks. Neurobiol Aging (2013) 1.25
Brain lesions on MRI in elderly patients with type 2 diabetes mellitus. Eur Neurol (2006) 1.24
Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clin Chem Lab Med (2011) 1.24
Simplified parametric methods for [11C]PIB studies. Neuroimage (2008) 1.23
Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol (2011) 1.22
Endogenous cortisol level interacts with noradrenergic activation in the human amygdala. Neurobiol Learn Mem (2006) 1.21
Differential regional atrophy of the cingulate gyrus in Alzheimer disease: a volumetric MRI study. Cereb Cortex (2006) 1.21
Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord (2014) 1.21
Age, hypertension, and lacunar stroke are the major determinants of the severity of age-related white matter changes. The LADIS (Leukoaraiosis and Disability in the Elderly) Study. Cerebrovasc Dis (2006) 1.20
Delayed rather than decreased BOLD response as a marker for early Alzheimer's disease. Neuroimage (2005) 1.20
Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement (2012) 1.20
Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia. J Neurol (2008) 1.18
Operational definitions for the NINDS-AIREN criteria for vascular dementia: an interobserver study. Stroke (2003) 1.17
Differential impact of cerebral white matter changes, diabetes, hypertension and stroke on cognitive performance among non-disabled elderly. The LADIS study. J Neurol Neurosurg Psychiatry (2007) 1.17
Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology (2012) 1.16
Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology (2013) 1.15
Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2009) 1.15
Incidence of depression and anxiety in the spouses of patients with dementia: a naturalistic cohort study of recorded morbidity with a 6-year follow-up. Am J Geriatr Psychiatry (2010) 1.14
Accelerating regional atrophy rates in the progression from normal aging to Alzheimer's disease. Eur Radiol (2009) 1.14
Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. J Nucl Med (2009) 1.14
White matter lesions and hippocampal atrophy in Alzheimer's disease. Neurology (2004) 1.14
Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same? Ann Neurol (2005) 1.14
Physical activity prevents progression for cognitive impairment and vascular dementia: results from the LADIS (Leukoaraiosis and Disability) study. Stroke (2012) 1.13
Diagnostic imaging of patients in a memory clinic: comparison of MR imaging and 64-detector row CT. Radiology (2009) 1.12
Corpus callosum atrophy is associated with mental slowing and executive deficits in subjects with age-related white matter hyperintensities: the LADIS Study. J Neurol Neurosurg Psychiatry (2006) 1.12